Severe (level 3) hypoglycaemia occurrence in a real-world cohort of adults with type 1 or 2 diabetes mellitus (iNPHORM, United States).

Alexandria A Ratzki-Leewing Jason E Black Angelica Cristello Sarteau Bridget L Ryan Guangyong Zou Neil Klar Kristina Timcevska Stewart B Harris

Published in: Diabetes, obesity & metabolism (2023)

iNPHORM is one of the first long-term, prospective US-based investigations on level 3 hypoglycaemia epidemiology. Our results underscore the importance of participant-reported data to ascertain its burden. Events were alarmingly frequent, irrespective of diabetes type, and concentrated in a small subsample.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
risk factors
electronic health record
early onset
big data
metabolic syndrome
skeletal muscle
drug induced